Genesis Health Sciences

One family of companies. One mission: microvascular health.

Genesis Health Sciences is the holding company behind the GlycoCalyx Research Institute and GlycoCheck™ — uniting twenty years of glycocalyx science, clinically-used measurement technology and restorative nutraceuticals under one roof.

Who we are

The holding company behind glycocalyx.com and GlycoCheck

Genesis Health Sciences exists because of a simple conviction: the microvasculature — the vast network of small vessels where blood actually meets tissue — is where health is won or lost. Everything our companies do is aimed at making that system measurable, restorable and provable.

At the centre of the family are two organisations. The GlycoCalyx Research Institute, established in 2012 by Dr Hans Vink and Robert Long, advances the science of the endothelial glycocalyx and develops the ReVasca™, ReCelyx™, and ReMyolyx™ nutraceutical lines. GlycoCheck brings the GlycoCheck™ measurement system — invented by Dr Vink — to clinics, hospitals and universities across the United States.

Illustration comparing a healthy endothelial glycocalyx with a compromised one
The endothelial glycocalyx — the protective gel lining of every blood vessel — healthy versus compromised. This layer is the shared subject of everything the family does.
300+Medical & research institutions worldwide
80+US medical clinic locations and growing
160+Peer-reviewed publications
20+Years of research
glycocalyx.com

GlycoCalyx Research Institute

Research · Education · Restorative nutraceuticals

Established in 2012, the Institute is dedicated to education and training on the endothelial glycocalyx and the microvascular system. It maintains a library of peer-reviewed research, teaches practitioners and the public, and develops nutraceuticals formulated to supply the building blocks of a healthy glycocalyx.

  • Education and training for practitioners and the public
  • A research library of peer-reviewed glycocalyx science
  • ReVasca™, ReCelyx™, and ReMyolyx™ — developed and validated alongside GlycoCheck™ measurement
A bottle of ReVasca capsules
ReVasca™ — the Institute’s flagship formulation.
A GlycoCheck assessment being performed under the tongue
A GlycoCheck™ assessment — non-invasive, under the tongue, under five minutes.
The GlycoCheck™ system

GlycoCheck™

Clinical measurement technology

GlycoCheck is the American home of the GlycoCheck™ system — a non-invasive, Class I medical device that films the capillaries under the tongue and computes a MicroVascular Health Score in under five minutes. It gives clinicians an objective way to see microvascular and glycocalyx health, track it over time, and show patients their progress.

  • Non-invasive assessment in under five minutes
  • An objective MicroVascular Health Score (MVHS)
  • In use at hospitals, clinics and universities — 80+ US locations and growing

How the family works together

Measure • Restore • Verify

The two companies are built to complete each other’s work: GlycoCheck™ makes microvascular health visible, the Institute’s science and formulations improve it, and a repeat measurement proves it.

M

Measure

Use the GlycoCheck™ System to objectively assess endothelial glycocalyx and microvascular health through a simple, non-invasive assessment performed under the tongue in under 5 minutes.

R

Restore

Develop personalised treatment strategies using ReVasca™, lifestyle medicine, nutrition, exercise and risk-factor reduction.

V

Verify

Repeat GlycoCheck™ assessments to objectively measure patient improvement, guide clinical decisions and document treatment effectiveness over time.

Our goals

What Genesis Health Sciences is building toward

  • Make microvascular health a standard, objective vital sign in everyday clinical practice
  • Advance the science of the endothelial glycocalyx through research and peer-reviewed publication
  • Develop restorative nutraceuticals whose effects can be measured — not just marketed
  • Equip and train a growing network of practitioners across the United States
  • Help the public understand that lasting health begins in the capillaries
Capillary imaging before and after 12 weeks, showing Microvascular Health Score rising
Microvascular Health Score before, and after 12 weeks taking ReVasca™. Individual results vary.

Leadership

The founders

Both companies trace back to the same two people — the scientist behind the measurement, and the developer who turned the science into practice.

Dr Hans Vink, PhD

Dr Hans Vink, PhD

Co-Founder & Chief Science Officer

Internationally recognised vascular scientist and a pioneer of endothelial glycocalyx research. Hans has spent more than two decades advancing our understanding of the glycocalyx and its role in microvascular health — work behind more than 160 peer-reviewed publications, validated by over 300 medical and research institutions worldwide.

Robert (Bob) Long

Robert (Bob) Long

Co-Founder & Chief Executive Officer

For more than 15 years Bob has worked alongside Hans to turn glycocalyx science from academic research into practical clinical tools — helping physicians, researchers and healthcare organisations implement GlycoCheck™ and build a category of medicine centred on objective measurement of vascular health.

Together, Hans and Bob have spent more than fifteen years building GlycoCheck™, ReVasca™ and the Glycocalyx Research Institute into one of the world’s leading organisations dedicated to endothelial glycocalyx research, education and clinical implementation.

Explore the family

Everything Genesis Health Sciences makes lives here on glycocalyx.com — the science, the research library, the GlycoCheck™ technology and the ReVasca™ range.